

The GDUFA II Pre-ANDA Program for Complex Products

Kris Andre

Associate Director of Regulatory Affairs Office of Research and Standards Office of Generic Drugs



What I'm Going to Cover

- Introduction to the Pre-ANDA meeting program
- Submitting a meeting request through the Portal
- The Pre-ANDA Process
- The Pre-ANDA Meeting Request and Package



The Pre-ANDA Program Goal

- The Pre-ANDA Program was established by GDUFA II
 - To clarify regulatory expectations for prospective applicants early in product development
 - Assist applicants to develop more complete submissions
 - Promote a more efficient and effective ANDA assessment process
 - Reduce the number of review cycles required to obtain ANDA approval, particularly for <u>Complex Products</u>



The Two Pre-ANDA Meeting Types

- Pre-ANDA meetings accelerate access to generics of complex products through early engagement with the FDA
 - Pre-ANDA Product development meetings (PDEV)
 - Early engagement in your individual product development program
 - Pre-Submission meetings (PSUB)
 - Ready to or close to submitting your application



Pre-ANDA Meeting Goal Dates

- Within 14 days FDA will respond to the request and grant or deny the meeting
- If a meeting is granted, FDA will offer a meeting date within 120 calendar days of granting the request
- Five days before the meeting you will receive preliminary written comments from FDA
- Meeting minutes will be sent 30 days after the meeting

Product Development Meetings

- A meeting involving a <u>scientific exchange</u> to discuss specific issues or questions
 - A novel proposed study design
 - Alternative bioequivalence approach
 - Additional study expectations
- FDA will provide <u>targeted advice</u> regarding an ongoing ANDA development program

FDA

Pre-Submission Meetings

FDA

- A meeting to discuss and explain the <u>format and</u> <u>content of an ANDA</u> to be submitted
- Applicants can obtain advice that will enable efficient review and improve the chance of first cycle approval
- Pre-submission meetings <u>will not</u> include substantive review of summary data or full study reports
- ANDA expected to be submitted within 6-12 months

Pre-ANDA Meeting Decision



- FDA will grant a prospective applicant a Product Development Meeting if, in FDA's judgment:
 - The meeting concerns development of a Complex Product for which FDA has not issued product-specific guidance or proposes an alternative equivalence evaluation (i.e., change in study type, such as in vitro to clinical) for a Complex Product for which FDA has issued product-specific guidance;
 - The prospective applicant submits a complete meeting package, including a data package and specific proposals;
 - A controlled correspondence response would not adequately address the prospective applicant's questions; and
 - A Product Development Meeting would significantly improve ANDA assessment efficiency.



Pre-ANDA Meeting Decision (cont.)

- A product development meeting may be granted if the meeting concerns complex product development issues other than those identified above (e.g., FDA has developed a product-specific guidance and the prospective ANDA applicant is not proposing an alternative equivalence evaluation), dependent on available resources, if:
 - The prospective applicant submits a complete meeting package, including a data package and specific proposals
 - A controlled correspondence response would not adequately address the prospective applicant's questions
 - A Product Development Meeting would significantly improve ANDA assessment efficiency



The CDER Direct NextGen Collaboration Portal

- Commonly called the "Portal"
- Use for pre-ANDA meeting requests for complex generic drug products
 - You will need a pre-assigned applicant number*
 - You will need a U.S. agent if you are a non-U.S. applicant
 - Pre-ANDA product development meetings
 - Pre-submission meetings

*<u>Requesting a Pre-Assigned Application number</u>



Create a Login for the Portal

- Once on the website, click Request a Login
- Choose Pre-ANDA Meetings as your "event"
- Register as either a U.S. agent or the applicant
- Enter the required information
- Once approved, you will receive your username and temporary password
- Login request will not be processed until you verify your email



Login FAQs

- My organization doesn't appear when I search
 You can enter it manually
- I don't have a DUNS number or I don't know what it is
 - Use the 9-digit code, 999999999
- Contact the EDM support team if needed at <u>EDMSupport@fda.hhs.gov</u>



U.S. Agents

- If you are submitting as a U.S. agent, fill in your applicant's information
 - Search for applicant information or enter manually
 - Provide the applicant contact information
- If you are the applicant, with no U.S. agent, proceed to "Attach a Document"
 - Do not enter yourself as a U.S. agent

My Login has been Created – Now What?

- Click "Create New Request"
- Enter required information
 - Pre-assignment number
 - What type of meeting request are you submitting
 - Reference Listed Drug (RLD)



Submitting Your Meeting Request

- Before you submit your request
 - You have the option of saving your draft meeting request
 - Come back to it later and continue where you left off
 - FDA cannot see saved meeting requests
- You can delete a meeting request if you have not yet submitted it
- You will be asked to review for accuracy
- Click "Submit to FDA"
- You will receive a confirmation message and email once you have submitted your request



Two-Way Communication

- Submit and receive documents through the Portal with email notification
- Advantage All your documents and correspondence in one place




Adding Your Documents

- You must add a meeting package in order to proceed
- You can add more than one document
 - Cover letter
 - Meeting package (due at time of request for a meeting)
- Multiple formats allowed
 - PDF, Microsoft Word, Microsoft Excel, Microsoft PowerPoint, Microsoft Access, SAS, and Text
 - Macros are not allowed
 - Files may not exceed 45 MB



Grant/Deny Assessment

- Within 14 days, FDA will respond to the request and grant or deny the meeting
- If a meeting is denied, FDA will provide information to the applicant on a path forward
- If a meeting is granted, FDA will offer a meeting date within 120 calendar days of granting the request



www.fda.gov

Meeting Package Format

FD A

- Refer to the draft guidance (Oct 2017)
 - Formal Meetings Between FDA and ANDA Applicants of Complex Products Under GDUFA Guidance for Industry
- Number your questions clearly and group them by discipline
 - e.g., Bioequivalence, CMC, etc.
- Minimize the use of sub-questions, for example a, b, c, etc.

https://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm578366.pdf



Meeting Package Content: Product Development Meetings

- Provide clear and specific questions about your development program
- Include data supporting the proposed new approach that may include
 - Characterization of the RLD and ANDA products
 - Results from pilot studies
 - Comparisons of the proposed approach to that currently recommended by FDA
 - Quantitative analysis (PBPK, PK/PD, or BE simulation) that supports your approach

Meeting Package Content: Pre-Submission Meetings



 Outline the unique, novel or complex aspects of your upcoming submission that you will present at the meeting

 If you have specific questions, provide appropriate background material and data related to those questions



Meeting Request Evaluation

- Assessment team will evaluate Pre-ANDA meeting requests
 - Office of Generic Drugs (OGD) and Office of Pharmaceutical Quality (OPQ) perform separate triage functions to determine whether to grant/deny and the extent of participation
 - OGD and OPQ coordinate to provide a unified response
 - The assessment team reviews the product details, contents and submitted questions in the meeting package
 - The assessment team determines whether the meeting is granted or denied



What Happens Next?

- A letter with the grant or deny decision will be sent to you through the portal
 - A meeting denied letter will complete your project
 - You will be advised on the next steps, for example, submit a controlled correspondence instead



My Meeting Was Granted

- Typically granted as face-to face meeting, though the applicant can request a written response or teleconference
- Information Requests (IR)
 - Sent to the applicant through the Portal
 - Can be sent to the applicant at any time
 - FDA strives to send early in the process
 - Applicant responds to the IR through the Portal under the SAME event ID, not as a new meeting request.



Preliminary Responses

- Preliminary responses for face-to-face meetings and teleconferences will be sent through the portal approximately five days before your scheduled meeting
- Your opportunity to focus your meeting for clarification
 - Submit presentation materials (not required) Do not submit until
 - Submit a revised agenda
 - Submit these through the portal

after you have received
your preliminary response

• You can cancel your meeting if you feel the preliminary responses adequately address your questions

Meeting Day



- Prospective ANDA applicant submits meeting slides and agenda via the Portal approximately 48 hours before
 - Meetings are typically 1 hour
 - Agenda should be focused on clarification or further discussion around the preliminary written comments
- Meeting participants discuss the data, questions, and the responses provided to assist the prospective ANDA applicant's complex product development program
- FDA cannot review new material presented at the meeting for the first time

www.fda.gov



After the Meeting

- The applicant can submit post meeting comments through the Portal
 - Within seven days of the meeting
- FDA will send the final meeting minutes through the Portal within 30 days of the meeting
- This completes the meeting request



Common Reasons for Denial

- Incomplete meeting packages
- Not a complex product
- Wrong meeting type chosen PDEV vs PSUB
- Should be a controlled correspondence
- PSG is available and not asking for an alternate bioequivalence route

Am I a Pre-submission or Product Development Meeting?



Product Development meetings are for discussion of specific scientific issues

- Proposed study design, alternative approach, additional study expectations
- Pre-submission meetings are for 6-12 months before submission
 - You are ready to submit
 - Do you have your stability batches started?
 - Discuss format and content of ANDA
 - Not a filing review

FDA

Am I a Controlled Correspondence or a Meeting?

- Standard controlled correspondence (aka controls) reviewed in 60 days
 - Use for guidance clarification and rapid input into development programs
- Complex controls reviewed in 120 days
 - Clinical input (protocols for Safety determination letters)
 - Alternate BE approach (within the same class)
- Complex control expands what we can consider via the control process
- Meetings are best for multidisciplinary questions
- Controls are for single questions or a small group of closely related questions



Examples of Unclear Questions

- Is my PK study acceptable?
 - Instead identify the point of uncertainty and ask a specific question
- Is my specification acceptable?
 - Instead ask a specific question about this complex product and your understanding of how you will control the CQA of your product
- Do not submit a protocol and ask us to review it
 - Instead submit specific questions regarding your protocol



Questions

- Are product development meetings good for broad questions?
 - No, you should provide specific questions and include justification.
- Should I submit my entire protocol for comment?
 - No, again, specific questions with data other justification.



Questions?

